PULMONARY EMBOLISM IN THE ONSET OF GENETIC HEMATOGENICAL THROMBOPHILIA
Abstract and keywords
Abstract (English):
Hematogenous thrombophilia is often encountered in the clinical practice of doctors of all specialties. The article presents current data on the diagnostic of this pathology. In most cases pulmonary embolism is a clinical onset of hereditary hematogenous thrombophilia. According to the authors of this article, pulmonary embolism occurred in 60% of surveyed patients with hereditary thrombophilia hematogenous. Current antithrombotic therapy is quite effective in this category of patients. Three cases of personal experience of the authors when there was diagnosed a combined form of hematogenous thrombophilia with serious thrombotic complications in anamnesis are shown. Adequate secondary prevention of thrombosis contributed to further disease-free course of the disease.

Keywords:
hematogenous thrombophilia, pulmonary embolism, treatment, prevention.
References

1. Barkagan Z.S. Prethrombotic state and thrombophilia. In: Vorobyov A.I., editor. Guide to Hematology. Moscow: Nyudiamed; 2005; Vol.3:133-147 (in Russian).

2. Voitsekhovskiy V.V., Landyshev Yu.S., Tseluyko S.S., Zabolotskikh T.V. Hemorrhagic syndrome in clinical practice. Blagoveshchensk: Odeon; 2014 (in Russian).

3. Voitsekhovskiy V.V. Dabigatran for prevention thrombosis in patients with hematogenous thrombophilia. Amurskiy meditsinskiy zhurnal 2014; 1:92−100 (in Russian).

4. Vorobiev A.I., Vasiliev S.A., Gorodetskiy V.M., Shevelev A.A., Gorgidze L.A., Kremenetskaya O.C., Shklovskiy-Kordi N.E. Hypercoagulation syndrome: classification, pathogenesis, diagnostics, and therapy. Gematologiya i transfuziologiya 2016; 61(3):116−122 (in Russian).

5. Vorobyeva N.M., Panchenko E.P., Ermolina O.V., Balaкhonova T.V., Dobrovolsky A.B., Titaev E.V., Кhasanova Z.B., Postnov A.Yu., Kirienko A.I. Prolongation of enoxaparin therapy to one month promotes recanalization of occlusively thrombosed deep veins. Terapevticheskiy arkhiv 2011; 83(8):33−37 (in Russian).

6. Galstyan G.M. Hemostasis disorders caused by deficiency of vitamin k-dependent coagulation factors: pathogenesis, correction methods and recommendations for treatment. Gematologiya i transfuziologiya 2012; 57(2):7−21 (in Russian).

7. Landyshev Yu.S., Lenshin A.A. Manual on Pulmonology. Blagoveshchensk: RIO; 2003 (in Russian).

8. Momot A.P., Cyvkina L.P., Taranenko I.A., Mamaev A.N., Serdyuk G.V., Shakhmatov I.I., Lydina I.V., Grigor´eva E.V., Belozerov D.E., Nikitina D.A., Strozenko L.A., Petrekova O.V., Bespalova O.V., Lomaev I.S. Modern methods of detection thrombotic state of readiness. Barnaul; 2011 (in Russian).

9. Approval of specialized medical care standard in pulmonary thromboembolism. Russian Ministry of Health Order on November 9th, 2012 N873n. Available at: www.rosminzdrav.ru (in Russian).

10. Sakharyuk A.P., Shimko V.V., Tarasyuk E.S., Verevetinov A.N., Rapovka V.G., Vavrinchuk S.A., Еmets A.N. Thromboembolism of pulmonary arteries in clinical practice. Bûlleten´ fiziologii i patologii dyhaniâ 2015; 55:48−53(in Russian).

11. Sakharyuk A.P., Shimko V.V., Tarasyuk E.S., Verevetinov A.N., Emets A.N. Surgical treatment of floating thrombosis of inferior vena cava system. Bûlleten´ fiziologii i patologii dyhaniâ 2015; 57:57−60 (in Russian).

12. Agnelli G., Buller H.R., Cohen A. Curto M., Gallus A.S., Johnson M., Porcari A., Raskob G.E., Weitz J.I.; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 2013; 368(8):699-708.

13. Bates S.M., Greer I., Pabinger I., Sofaer S., Hirsh J.; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl.): 844S-886S.

14. Brandjes D.P.M., Heijboer H., Buller H.R., de Rijk M., Jagt H., ten Cate J.W. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N. Engl. J. Med. 1992; 327(21):1485-1489.

15. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., Prins M.H., Hettiarachchi R., Hantel S., Schnee J., Büller H.R., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9604):949-956.

16. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., Kälebo P., Christiansen A.V., Hantel S., Hettiarachchi R., Schnee J., Büller H.R; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 2007; 5(11):2178-2185.

17. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., Bandel T.J., Beckmann H., Muehlhofer E., Misselwitz F., Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358(26):2765−2775.

18. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., Garcia D., Geraldes M., Gersh B.J., Golitsyn S., Goto S., Hermosillo A.G., Hohnloser S.H., Horowitz J., Mohan P., Jansky P., Lewis B.S., Lopez-Sendon J.L., Pais P., Parkhomenko A., Verheugt F.W., Zhu J., Wallentin L.;ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365(11):981-992.

19. Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting. Bull .World. Health. Organ. 1997; 75(3):177-189.

20. Kaatz S., Kouides P.A., Garcia D.A., Spyropolous A.C., Crowther M., Douketis J.D., Chan A.K., James A., Moll S., Ortel T.L., Van Cott E.M., Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 2012; 87(Suppl.1):141-145.

21. McKellar S.H., Abel S., Camp C.L., Suri R.M., Ereth M.H., Schaff H.V. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J. Thorac. Cardiovasc. Surg. 2011; 141(6):1410-1416.

22. Patel M.R., Mahaffey K.W., Garg J., Pan Guohua, Singer D.E., Werner H., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A.A., Califf R.M.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365(10):883-891.

23. Raskob G.E., Gallus A.S., Pineo G.F., Chen D., Ramirez L-M., Wright R. T., Lassen M. R. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J. Bone Joint Surg. Br. 2012; 94(2):257-264.

24. Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz S.D., Misselwitz F., Bandel T.J., Homering M., Westermeier T., Kakkar A.K. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 2011; 105(3):444-453.

Login or Create
* Forgot password?